Cargando…

Cost-effectiveness of therapeutic infant formulas for cow's milk protein allergy management

Cow's milk protein allergy (CMPA) is children's most common food allergy. Therapeutic infant formulas for CMPA lead to symptom-free and potentially benefit early tolerance induction and reducing the allergic march in non-breastfed babies. This study assessed the cost-effectiveness of CMPA...

Descripción completa

Detalles Bibliográficos
Autores principales: Suratannon, Narissara, Prapansilp, Panote, Srinarongsook, Athitaya, Tanpowpong, Pornthep, Chatchatee, Pantipa, Pongpirul, Krit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281430/
https://www.ncbi.nlm.nih.gov/pubmed/37346906
http://dx.doi.org/10.3389/fnut.2023.1099462
_version_ 1785061003794317312
author Suratannon, Narissara
Prapansilp, Panote
Srinarongsook, Athitaya
Tanpowpong, Pornthep
Chatchatee, Pantipa
Pongpirul, Krit
author_facet Suratannon, Narissara
Prapansilp, Panote
Srinarongsook, Athitaya
Tanpowpong, Pornthep
Chatchatee, Pantipa
Pongpirul, Krit
author_sort Suratannon, Narissara
collection PubMed
description Cow's milk protein allergy (CMPA) is children's most common food allergy. Therapeutic infant formulas for CMPA lead to symptom-free and potentially benefit early tolerance induction and reducing the allergic march in non-breastfed babies. This study assessed the cost-effectiveness of CMPA management with different therapeutic infant formulas in Thailand, which may reflect situations in developing countries throughout Asia. An analytic decision model was developed to simulate the occurrence of eczema, urticaria, asthma, rhinoconjunctivitis, or being symptom-free in infants with CMPA over 36 months. Extensively hydrolyzed casein formula with added probiotic Lacticaseibacillus rhamnosus (previously Lactobacillus rhamnosus) strain GG (EHCF+LGG), extensively hydrolyzed whey formula (EHWF), soy protein-based formula (SPF), and amino acid formula (AAF) were compared from the healthcare payer perspective. The results from a prospective cohort study were used for comparative effectiveness measures, while local experts were interviewed to estimate the healthcare resource used in the management of CMPA. The costs of healthcare resources were obtained from standard, publicly available sources. The direct medical cost of CMPA management was lowest for EHCF+LGG (USD 1,720), followed by SPF (USD 2,090), EHWF (USD 2,791), and AAF (USD 7,881). Compared with other formulas, EHCF+LGG was expected to save USD 370 (SPF), USD 1,071 (EHWF), and USD 6,161 (AAF) in the total cost of CMPA management over 36 months. In conclusion, EHCF+LGG was the most cost-effective strategy for managing non-breastfed infants with CMPA. This strategy was associated with more children developing immune tolerance to cow's milk and being symptom-free, contributing to overall cost-saving potential.
format Online
Article
Text
id pubmed-10281430
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102814302023-06-21 Cost-effectiveness of therapeutic infant formulas for cow's milk protein allergy management Suratannon, Narissara Prapansilp, Panote Srinarongsook, Athitaya Tanpowpong, Pornthep Chatchatee, Pantipa Pongpirul, Krit Front Nutr Nutrition Cow's milk protein allergy (CMPA) is children's most common food allergy. Therapeutic infant formulas for CMPA lead to symptom-free and potentially benefit early tolerance induction and reducing the allergic march in non-breastfed babies. This study assessed the cost-effectiveness of CMPA management with different therapeutic infant formulas in Thailand, which may reflect situations in developing countries throughout Asia. An analytic decision model was developed to simulate the occurrence of eczema, urticaria, asthma, rhinoconjunctivitis, or being symptom-free in infants with CMPA over 36 months. Extensively hydrolyzed casein formula with added probiotic Lacticaseibacillus rhamnosus (previously Lactobacillus rhamnosus) strain GG (EHCF+LGG), extensively hydrolyzed whey formula (EHWF), soy protein-based formula (SPF), and amino acid formula (AAF) were compared from the healthcare payer perspective. The results from a prospective cohort study were used for comparative effectiveness measures, while local experts were interviewed to estimate the healthcare resource used in the management of CMPA. The costs of healthcare resources were obtained from standard, publicly available sources. The direct medical cost of CMPA management was lowest for EHCF+LGG (USD 1,720), followed by SPF (USD 2,090), EHWF (USD 2,791), and AAF (USD 7,881). Compared with other formulas, EHCF+LGG was expected to save USD 370 (SPF), USD 1,071 (EHWF), and USD 6,161 (AAF) in the total cost of CMPA management over 36 months. In conclusion, EHCF+LGG was the most cost-effective strategy for managing non-breastfed infants with CMPA. This strategy was associated with more children developing immune tolerance to cow's milk and being symptom-free, contributing to overall cost-saving potential. Frontiers Media S.A. 2023-06-22 /pmc/articles/PMC10281430/ /pubmed/37346906 http://dx.doi.org/10.3389/fnut.2023.1099462 Text en Copyright © 2023 Suratannon, Prapansilp, Srinarongsook, Tanpowpong, Chatchatee and Pongpirul. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Nutrition
Suratannon, Narissara
Prapansilp, Panote
Srinarongsook, Athitaya
Tanpowpong, Pornthep
Chatchatee, Pantipa
Pongpirul, Krit
Cost-effectiveness of therapeutic infant formulas for cow's milk protein allergy management
title Cost-effectiveness of therapeutic infant formulas for cow's milk protein allergy management
title_full Cost-effectiveness of therapeutic infant formulas for cow's milk protein allergy management
title_fullStr Cost-effectiveness of therapeutic infant formulas for cow's milk protein allergy management
title_full_unstemmed Cost-effectiveness of therapeutic infant formulas for cow's milk protein allergy management
title_short Cost-effectiveness of therapeutic infant formulas for cow's milk protein allergy management
title_sort cost-effectiveness of therapeutic infant formulas for cow's milk protein allergy management
topic Nutrition
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281430/
https://www.ncbi.nlm.nih.gov/pubmed/37346906
http://dx.doi.org/10.3389/fnut.2023.1099462
work_keys_str_mv AT suratannonnarissara costeffectivenessoftherapeuticinfantformulasforcowsmilkproteinallergymanagement
AT prapansilppanote costeffectivenessoftherapeuticinfantformulasforcowsmilkproteinallergymanagement
AT srinarongsookathitaya costeffectivenessoftherapeuticinfantformulasforcowsmilkproteinallergymanagement
AT tanpowpongpornthep costeffectivenessoftherapeuticinfantformulasforcowsmilkproteinallergymanagement
AT chatchateepantipa costeffectivenessoftherapeuticinfantformulasforcowsmilkproteinallergymanagement
AT pongpirulkrit costeffectivenessoftherapeuticinfantformulasforcowsmilkproteinallergymanagement